Fibrosis is associated with adiponectin resistance in chronic hepatitis C virus infection

European Journal of Clinical Investigation

Volumn 41, Issue 8, 2011, Pages 898-905

  Corbetta, Sabrina ^a   Redaelli, Alessandro ^b   Pozzi, Massimo ^c   Bovo, Giorgio ^c   Ratti, Laura ^c   Redaelli, Elena ^c   Pellegrini, Caterina ^a   Beck Peccoz, Paolo ^a   Spada, Anna ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b AO San Gerardo   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Adiponectin; Adiponectin receptors; Fibrosis; HCV hepatitis; Insulin

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; MESSENGER RNA; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HEPATITIS C; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ADIPONECTIN; ADULT; ANALYSIS OF VARIANCE; BODY MASS INDEX; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RECEPTORS, ADIPONECTIN; RNA, MESSENGER; TRIGLYCERIDES;

EID: 79960100833     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02498.x     Document Type: Article

References (34)

1. Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005;54:1003-8.
2. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG et al. Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression. Gastroenterology 2003;125:1695-704.
3. Romero-Gomez M. Insulin resistance and hepatitis C. World J Gastroenterol 2006;12:7075-80.
4. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004;126:840-8.
5. Pittas AG, Joseph NA, Greenberg AS. Adipocytokines and insulin resistance. J Clin Endocrinol Metab 2004;89:447-52.
6. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001;7:947-53.
7. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-6.
8. Nawrocki AR, Rajala MW, Tomas E, Pajvani UB, Saha AK, Trumbauer ME et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 2006;281:2654-60.
9. Sheikh MY, Choi J, Qadri I, Friedman JE, Sanyal AJ. Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology 2008;47:2127-33.
10. Kaser S, Moschen A, Kaser A, Ludwiczek O, Ebenbichler CF, Vogel W et al. Circulating adiponectin reflects severity of liver disease but not insulin sensitivity in liver cirrhosis. J Intern Med 2005;258:274-80.
11. Tacke F, Wusterfeld T, Horn R, Luedde T, Srinivas Rao A, Manns MP et al. High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J Hepatol 2005;42:666-73.
12. Cua IHY, Hui JM, Bandara P, Kench JG, Farrell GC, McCaughan GW et al. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology 2007;46:66-73.
13. Petit JM, Minello A, Jooste V, Bour JB, Galland F, Duvillard L et al. Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients. J Clin Endocrinol Metab 2005;90:2240-3.
14. Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005;54:117-21.
15. Liu CJ, Chen PJ, Jeng YM, Huamg WL, Yang WS, Lai MY et al. Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. J Hepatol 2005;43:235-42.
16. Jonsson JR, Moschen AR, Kickman IJ, Richardson MM, Kaser S, Clouston AD et al. Adiponectin and its receptors in patients with chronic hepatitis C. J Hepatol 2005;43:929-36.
17. Ronchi CL, Corbetta S, Cappiello V, Morpurgo PS, Giavoli C, Beck-Peccoz P et al. Circulating adiponectin levels and cardiovascular risk factors in acromegalic patients. Eur J Endocrinol 2004;150:663-9.
18. Bergman RN, Prager R, Volund A, Olefsky JM. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 1987;79:790-800.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
20. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
21. Marchetti A, Pellegrini C, Buttitta F, Falleni M, Romagnoli S, Felicioni L et al. Prediction of survival in stage I lung carcinoma patients by telomerase function evaluation. Lab Invest 2002;83:6854-7.
22. Corbetta S, Bulfamante G, Cortelazzi D, Barresi V, Cetin I, Mantovani G et al. Adiponectin expression in human fetal tissues during mid- and late gestation. J Clin Endocrinol Metab 2005;90:2397-402.
23. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
24. Palmer C, Hampartzoumian T, Lloyd A, Zekry A. A novel role for adiponectin in regulating the immune responses in chronic hepatitis C virus infection. Hepatology 2008;48:374-84.
25. Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 2003;125:1796-807.
26. Neumeier M, Hellerbrand C, Gabele E, Buettner R, Bollheimer C, Weigert J et al. Adiponectin and ist receptors in rodent models of fatty liver disease and liver cirrhosis. World J Gastroenterol 2006;12:5490-4.
27. Felder TK, Hahne P, Soyal SM, Miller K, Hoffinger H, Oberkofler H et al. Hepatic adiponectin receptors (ADIPOR) 1 and 2 mRNA and their relation to insulin resistance in obese humans. Int J Obes (Lond) 2010;34:846-51.
28. Cua IH, Hui JM, Kench JG, George J. Genotype-specific interactions of insulin resistance, steatosis and fibrosis in chronic hepatitis C. Hepatology 2008;48:723-31.
29. Tsuchida A, Yamauchi T, Ito Y, Hada Y, Maki T, Takekawa S et al. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem 2004;279:30817-22.
30. Nannipieri M, Cecchetti F, Anselmino M, Mancini E, Marchetti G, Bonotti A et al. Pattern of expression of adiponectin receptors in human liver and its relation to nonalcoholic steatohepatitis. Obes Surg 2009;19:467-74.
31. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007;13:332-9.
32. Banerjee A, Meyer K, Mazumdar B, Ray RB, Ray R. Hepatitis C virus differentially modulates activation of forkheadtranscription factors and insulin-induced metabolic gene expression. J Virol 2010;84:5936-46.
33. Wedemeyer I, Bechmann LP, Odenthal M, Jochum C, Marquitan G, Drebber U et al. Adiponectin inhibits steatotic CD95/Fas up-regulation by hepatocytes: therapeutic implications for hepatitis C. J Hepatol 2009;50:140-9.
34. Balmer ML, Joneli J, Schoepfer A, Stickel F, Thormann W, Dufour JF. Significance of serum adiponectin levels in patients with chronic liver disease. Clin Sci (Lond) 2010;119:431-6.